UBS Group AG Sells 91,570 Shares of Emergent Biosolutions Inc. $EBS

UBS Group AG reduced its stake in Emergent Biosolutions Inc. (NYSE:EBS) by 20.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 347,805 shares of the biopharmaceutical company’s stock after selling 91,570 shares during the quarter. UBS Group AG owned about 0.66% of Emergent Biosolutions worth $4,299,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Legal & General Group Plc bought a new position in Emergent Biosolutions in the 2nd quarter valued at about $31,000. Raymond James Financial Inc. bought a new position in Emergent Biosolutions in the 2nd quarter valued at about $53,000. Farther Finance Advisors LLC raised its holdings in Emergent Biosolutions by 361.3% in the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 4,827 shares during the period. BNP Paribas Financial Markets raised its holdings in Emergent Biosolutions by 133.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,942 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 6,246 shares during the period. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Emergent Biosolutions in the 3rd quarter valued at about $100,000. 78.40% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EBS. Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. HC Wainwright lowered their price target on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Finally, Weiss Ratings cut shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Emergent Biosolutions currently has an average rating of “Hold” and a consensus target price of $12.00.

Emergent Biosolutions Stock Up 1.4%

Shares of EBS opened at $8.49 on Friday. Emergent Biosolutions Inc. has a 12 month low of $5.61 and a 12 month high of $14.06. The firm’s 50 day moving average is $8.31 and its 200-day moving average is $10.16. The stock has a market capitalization of $438.17 million, a PE ratio of -30.30 and a beta of 2.33. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The company had revenue of $156.10 million for the quarter, compared to analysts’ expectations of $145.00 million.

Insider Buying and Selling at Emergent Biosolutions

In other news, Director Kathryn C. Zoon sold 17,202 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $144,496.80. Following the transaction, the director directly owned 79,941 shares of the company’s stock, valued at approximately $671,504.40. This trade represents a 17.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Donald W. Degolyer sold 15,481 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $130,040.40. Following the transaction, the director directly owned 129,721 shares in the company, valued at $1,089,656.40. This represents a 10.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,925 shares of company stock valued at $518,312 over the last ninety days. Company insiders own 6.00% of the company’s stock.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.